Back to today’s briefing

Story perspectives

FDA Approves Game-Changing Breast Cancer Treatment: Hope Renewed

1/19/2025

37 8

Summary

Story summary

The FDA has granted approval for datopotamab deruxtecan-dlnk, a groundbreaking treatment for adults battling unresectable or metastatic HR-positive, HER2-negative breast cancer after prior endocrine therapy and chemotherapy. This decision stems from the promising TROPION-Breast01 trial, which revealed a significant boost in progression-free survival and response rates, offering new hope to patients.

1 of 1

Story summary

The FDA has granted approval for datopotamab deruxtecan-dlnk, a groundbreaking treatment for adults battling unresectable or metastatic HR-positive, HER2-negative breast cancer after prior endocrine therapy and chemotherapy. This decision stems from the promising TROPION-Breast01 trial, which revealed a significant boost in progression-free survival and response rates, offering new hope to patients.